Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Huntington's Disease
Interventions: PF-02545920, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gonococcal Infection
Interventions: Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 36 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Appendicitis, Perforated Appendicitis, Ruptured Appendicitis, Complicated Appendicitis
Interventions: Early Appendectomy, Interval Appendectomy, Antibiotics; Procedure · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, OPC-14597; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 8 more

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 3 more

Conditions: Bacterial Conjunctivitis
Interventions: Gatifloxacin 0.5% eye drops, placebo eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 1 Year and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Downey, California

Conditions: Chronic Rhinosinusitis
Interventions: oral levofloxacin, nebulized levofloxacin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Community Acquired Pneumonia
Interventions: Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg; Drug
Lead sponsor: IASO Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more

Conditions: Depressive Disorder, Major
Interventions: Aripiprazole; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Tract Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 31
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 25 more

Conditions: Bipolar Disorder
Interventions: Lamotrigine + Aripiprazole, Lamotrigine + Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 55 more

Conditions: Schizophrenia
Interventions: PF-02545920, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 44
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 35 more

Conditions: Obesity, Critical Illness
Interventions: Levofloxacin 750 mg IV; Drug
Lead sponsor: Joel Thompson, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy
Interventions: ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg), Placebo vehicle (PBS); Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions: Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics; Combination Product · Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more

Conditions: Community Acquired Bacterial Pneumonia
Interventions: Delafloxacin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more

Conditions: Microbiota, Anti-bacterial Agents
Interventions: Levofloxacin, Azithromycin, Cefpodoxime; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Cysts
Interventions: Ciprofloxacin, Placebo (for ciprofloxacin); Drug · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cataract Surgery
Interventions: Gatifloxacin, Ketorolac LS, Pred Forte, Moxifloxacin, Nepafenac, EconoPred Plus; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Autistic Disorder, Asperger Syndrome, Autism Spectrum Disorder
Interventions: aripiprazole; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Months to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions: Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate; Drug · Procedure
Lead sponsor: Baylor Research Institute; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Temple, Texas

Conditions: Bacteriuria, Urinary Tract Infections, Asymptomatic Infections, Transplantation Infection
Interventions: Antibiotic; Drug
Lead sponsor: Rice, James C., M.D.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Schizophrenia
Interventions: SEP363856 150 mg, Placebo, moxifloxacin 400 mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more

Search by objective public record fields.

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Experimental Human Infection With Neisseria Gonorrhoeae

Optimal Care of Complicated Appendicitis

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

Abilify as an Adjunctive Treatment for Refractory Depression

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Levofloxacin Pharmacokinetics (PK) in the Severely Obese

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Healthy Patients & Effect of Antibiotics

A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration

Therapeutic Variables in Cataract Surgery

Study of Aripiprazole to Treat Children and Adolescents With Autism

Role of Prophylactic Postoperative Antibiotics in HoLEP

Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.